|
Ischemia-Modified Albumin in Acute Stroke.
Cerebrovasc Dis. 2006 Dec 1;23(2-3):216-220
Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, Mazighi M, Dehoux M, Benessiano J, Steg PG, Amarenco P.
Department
of Neurology and Stroke Center, Bichat University Hospital, Denis
Diderot University and Medical School, Paris, France.
Background:
Ischemia-modified albumin (IMA)is a new biological marker of ischemia.
Previous studies have found increased serum IMA levels after myocardial
ischemia, but no study has investigated the possibility that stroke
modifies IMA blood levels.
Materials and Methods: We studied 118
consecutive patients presenting within 3 h of the onset of an acute
neurological deficit [84 brain infarctions (BI), 18 brain hemorrhages
(ICH) and 16 transient ischemic attacks lasting less than 1 h or
epileptic seizures]. Serum samples were obtained for all patients at
initial presentation and repeated only in patients with stroke at 6, 12
and 24 h. IMA was measured by the albumin-cobalt-binding test (Ischemia
Technologies, Denver, Colo., USA). Results: The initial median IMA
(bootstrap 95% confidence interval, CI) was 83 U/ml (79-86) and 86 U/ml
(75-90) in patients with BI and ICH, respectively (p = 0.76), and was
73 U/ml (58-79) in others (p = 0.003 compared with BI, and p = 0.017
with ICH). Baseline IMA levels correlated with the National Institutes
of Health Stroke Scale [Spearman correlation coefficient: 0.34 (p =
0.002) in BI, 0.61 (p = 0.008) in ICH]. During the first 24 h, IMA
levels increased in BI patients (median, 9.1%; bootstrap 95% CI,
5.2-11.5), whereas no change was observed in ICH patients (median,
1.2%; bootstrap 95% CI, -7.8 to 6.8). Conclusions: IMA blood levels may
be a biomarker for early identification of acute stroke. Further
studies are required to investigate the role of IMA in the early
detection of acute stroke. Copyright (c) 2007 S. Karger AG, Basel.
|
